IDSA GUIDELINES Bundle (free trial)


IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, Enjoy!

Issue link:

Contents of this Issue


Page 16 of 17

ÎFor isolates with a vancomycin MIC ≤ 2, eg, "susceptible" according to CLSI breakpoints, the patient's clinical response should determine the continued use of vancomycin, independent of the MIC (A-III). > If the patient has had a clinical and microbiologic response to vancomycin, then it may be continued with close follow-up > If the patient has not had a clinical or microbiologic response to vancomycin despite adequate debridement and removal of other foci of infection, an alternative to vancomycin is recommended regardless of MIC. ÎFor isolates with a vancomycin MIC > 2 mcg/mL, eg, vancomycin- intermediate (VISA) or vancomycin-resistant (VRSA), an alternative to vancomycin should be used (A-III). Persistent MRSA Bacteremia and Vancomycin Treatment Failures in Adults ÎA search for and removal of other foci of infection, drainage or surgical debridement is recommended (A-III). ÎHigh-dose daptomycin, if the isolate is susceptible, in combination with other agents should be considered (B-III). > Please see antibiotic recommendations in full text guidelines for details at ÎIf reduced susceptibility to vancomycin and daptomycin are present, options may include: quinupristin-dalfopristin 7.5 mg/kg/dose IV every 8 hours, trimethoprim/sulfamethoxazole 5 mg/kg/dose IV twice daily, linezolid 600 mg PO/IV twice daily, or telavancin 10 mg/kg/ dose IV once daily (C-III). These options may be given as a single agent or in combination with other antibiotics. 15 S . a u r e u s S . a u r e u s

Articles in this issue

Links on this page

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - MRSA